scholarly journals Optimizing Macronutrients in People with Diabetes

2018 ◽  
Vol 06 (02) ◽  
pp. 065-071 ◽  
Author(s):  
Lovely Gupta ◽  
Priti Lal ◽  
Deepak Khandelwal

AbstractDiverse dietary practices and nutritional counseling strategies are followed in the management of diabetes and its comorbidities. The dietary approaches practiced in India make use of calorie and nutrient counting to ensure patient-centered nutrition therapy in diabetes management. Macronutrient modulation is a central pillar of patient-centered medical nutrition therapy (MNT). Carbohydrates (CHO) are considered as the predominant macronutrient affecting postprandial blood glucose levels. The insulin-to-CHO ratio is used for calculating mealtime insulin doses among patients on insulin regimen. The aim of this article is to highlight challenges faced in planning MNT, modifying recommended dietary allowances for persons with diabetes, and suggesting solutions to overcome these. It also aims to understand the requirement of individual macronutrients and their impact on glycemia as well as insulin dose adjustment.

2019 ◽  
Vol 2019 ◽  
pp. 1-3 ◽  
Author(s):  
Taha Alrifai ◽  
Faisal Shaukat Ali ◽  
Sameer Saleem ◽  
Diana Carolina Miranda Ruiz ◽  
Dana Rifai ◽  
...  

Immune checkpoint inhibitors (ICPIs) are a breakthrough therapy in oncology and have been approved by the Food and Drug Administration for the treatment of several malignancies. ICPIs have been reported to cause immune-mediated damage of islet cells leading to ICPI-induced type 1 diabetes mellitus (T1DM). These reports described patients presenting with severe diabetic ketoacidosis (DKA). We present a case of a 69-year-old Caucasian male with type 2 diabetes suffering from non-small cell lung cancer and undergoing treatment with pembrolizumab, an anti-programmed cell death protein-1 antibody, who presented to our emergency department with complaints of nausea, vomiting, polyuria, and polydipsia. He was found to have high anion gap metabolic acidosis with ketosis and elevated blood glucose levels consistent with DKA. Lab workup was consistent with T1DM. Despite being on a tailored insulin regimen, his blood glucose remained elevated, necessitating the addition of metformin to his regimen which effectively controlled his blood glucose.


2020 ◽  
pp. 193229682097981
Author(s):  
Sarah M. McGaugh ◽  
Stephanie Edwards ◽  
Howard Wolpert ◽  
Dessi P. Zaharieva ◽  
Nany Gulati ◽  
...  

Maintaining blood glucose levels in the target range during exercise can be onerous for people with type 1 diabetes (T1D). Using evidence-based research and consensus guidelines, we developed an exercise advisor app to reduce some of the burden associated with diabetes management during exercise. The app will guide the user on carbohydrate feeding strategies and insulin management strategies before, during, and after exercise and provide targeted and individualized recommendations. As a basis for the recommendations, the decision trees for the app use various factors including the type of insulin regimen, time of activity, previous insulin boluses, and current glucose level. The app is designed to meet the various needs of people with T1D for different activities to promote safe exercise practices.


2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Ivana Jankovic ◽  
Xiran Liu ◽  
Jonathan H Chen

Abstract The current optimal inpatient diabetes management schema involves administration of basal, prandial, and correctional insulin to maintain blood glucose (BG) within a target range. Nonetheless, practical management often fails to reach the ideal in both insulin dosing regimens and patients’ BG outcomes. Given the challenges of achieving adequate BG control for hospitalized patients using guidelines and expert knowledge alone, we attempted to use machine learning methods to predict (1) individual BGs, (2) average daily BGs, and (3) physician-ordered insulin doses based on data in an electronic health record-based repository between January 2014 and December 2018. We considered inpatients on subcutaneous insulin having a BG ≥ 200 mg/dL or ≤ 70 mg/dL or with an A1c percentage ≥ 6.5%. We excluded those missing critical data (such as weight), with fewer than five BG checks in 72 hours, or those on hemodialysis, resulting in a cohort of 3,461 patients with 175,934 BG checks among them. In this cohort, the average age was 61.4 years, the average A1c was 7.1%, and the average BG was 171.6 mg/dL, with approximately 25% of BGs ≥ 200 mg/dL and 1.7% of BGs < 70 mg/dL. Using linear regression, we identified features that contributed most to prediction of each of the outcomes. For all three outcomes, the average glucose in the past 24 hours was the most important feature. For prediction of glucose levels, previous BG, BG at the same time the previous day, A1c, BG variance, recent long-acting insulin dose, and glucocorticoid dose were all in the top 10 features. Similar features were important for predicting physician-ordered insulin doses. Surprisingly, neither weight nor creatinine were identified as top features for any outcome. Using these features in our predictive model, we found that individual BGs were highly erratic and could not be predicted precisely (R2 0.24). Similarly, and perhaps unsurprisingly, how physicians would order insulin for patients was also difficult to predict (R2 0.25). However, average daily glucose levels were predicted more reliably (R2 0.36), as was prediction of frank hyperglycemia (BG ≥ 200 mg/dL) in the next day (sensitivity 0.73, specificity 0.79). Given the typical practice pattern of a clinician evaluating the previous day’s insulin regimen performance and adjusting it by anticipating BGs for the next day, prediction of hyperglycemia in the next 24 hours can support decision-making for inpatient BG management.


Author(s):  
Nina Meloncelli ◽  
Shelley A. Wilkinson ◽  
Susan de Jersey

AbstractGestational diabetes mellitus (GDM) is a common pregnancy disorder and the incidence is increasing worldwide. GDM is associated with adverse maternal outcomes which may be reduced with proper management. Lifestyle modification in the form of medical nutrition therapy and physical activity, as well as self-monitoring of blood glucose levels, is the cornerstone of GDM management. Inevitably, the search for the “ultimate” diet prescription has been ongoing. Identifying the amount and type of carbohydrate to maintain blood glucose levels below targets while balancing the nutritional requirements of pregnancy and achieving gestational weight gain within recommendations is challenging. Recent developments in the area of the gut microbiota and its impact on glycemic response add another layer of complexity to the success of medical nutrition therapy. This review critically explores the challenges to dietary prescription for GDM and why utopia may never be found.


2016 ◽  
Vol 52 (4) ◽  
pp. 761-769 ◽  
Author(s):  
Any de Castro Ruiz Marques ◽  
Fabiana Percinoto Monteiro Schiavon ◽  
Patricia Batista Travassos ◽  
Vanessa Fontana Eik ◽  
Guilherme Godoy ◽  
...  

Author(s):  
E.Yu. Pyankova ◽  
◽  
L.A. Anshakova ◽  
I.A. Pyankov ◽  
S.V. Yegorova ◽  
...  

The problems of complications of diabetes mellitus cannot be solved without constant monitoring of blood glucose levels. The evolution of additional technologies for the determination of glucose in the blood of the last decades makes it possible to more accurately predict the risks of complications, both in the individual and in the patient population as a whole. The article provides an overview of the methods used in modern diabetology, facilitating control over the variability of blood glucose levels and helping in a more accurate selection of glucose-lowering therapy. All presented methods are currently working in real clinical practice in the Khabarovsk Krai


2020 ◽  
Vol 9 (11) ◽  
pp. 3635
Author(s):  
Rajat Kapoor ◽  
Lava R. Timsina ◽  
Nupur Gupta ◽  
Harleen Kaur ◽  
Arianna J. Vidger ◽  
...  

Beta cell dysfunction is suggested in patients with COVID-19 infections. Poor glycemic control in ICU is associated with poor patient outcomes. This is a single center, retrospective analysis of 562 patients in an intensive care unit from 1 March to 30 April 2020. We review the time in range (70–150 mg/dL) spent by critically ill COVID-19 patients and non-COVID-19 patients, along with the daily insulin use. Ninety-three in the COVID-19 cohort and 469 in the non-COVID-19 cohort were compared for percentage of blood glucose TIR (70–150 mg/dL) and average daily insulin use. The COVID-19 cohort spent significantly less TIR (70–150 mg/dL) compared to the non-COVID-19 cohort (44.4% vs. 68.5%). Daily average insulin use in the COVID-19 cohort was higher (8.37 units versus 6.17 units). ICU COVID-19 patients spent less time in range (70–150 mg/dL) and required higher daily insulin dose. A higher requirement for ventilator and days on ventilator was associated with a lower TIR. Mortality was lower for COVID-19 patients who achieved a higher TIR.


2018 ◽  
Vol 71 (6) ◽  
pp. 283-288
Author(s):  
Seiichiro Aoe ◽  
Kozo Komae ◽  
Yutaka Inoue ◽  
Isamu Murata ◽  
Yuki Minegishi ◽  
...  

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Junnan Shi ◽  
Hao Hu ◽  
Joanna Harnett ◽  
Xiaoting Zheng ◽  
Zuanji Liang ◽  
...  

Abstract Background Nutraceuticals containing traditional Chinese medicine (TCM) are promoted for use in the management of diabetes. The evidence to support such use is largely unknown. This study aimed to summarise and evaluate the literature reporting the results of randomized controlled trials (RCTs) investigating the effects of nutraceuticals in people living with diabetes. Methods Literature from four electronic databases (PubMed, Scopus, CINAHL and Web of Science) was searched following PRISMA guidelines to yield RCT publications on nutraceutical for diabetes management published since 2009. The quality of reporting was assessed using the CONSORT 2010 checklist statement. Risk-of-bias for each study was assessed using the Cochrane risk of bias tool. Results Out of 1978 records identified in the initial search, 24 randomized, double/triple-blinded, controlled trials that investigated the effect of nutraceuticals covering 17 different TCM herbs for diabetes management were selected. Participants included people who were diabetic (n = 16), pre-diabetic (n = 3) or predisposed to diabetes (n = 5). Sample sizes ranged between 23 and 117 for 2 arms, or 99–165 for 3 arms. Comparisons were made against placebo (n = 22), conventional medicine (n = 1), or regular diet (n = 1) for a duration between 4 and 24 weeks. All but one study tested the effect on fasting blood glucose levels (n = 23) or glycated haemoglobin levels (n = 18), and/or postprandial 2-h blood glucose levels (n = 4) as the primary outcomes. Nineteen studies reported some statistically significant reductions in the respective measures while 5 studies showed no effect on primary or secondary outcomes. None of the included studies met all the criteria for the CONSORT guidelines. Incomplete reporting about randomization and blinding, and a lack of ancillary analyses to explore other influential factors and potential harms associated with the use were repeatedly noted. Based on the Cochrane risk-of-bias tool, 19 studies were deemed to have a high risk of bias mainly attributed to sponsor bias. Conclusions There is some evidence to suggest positive clinical outcomes in response to the administration of a range of nutraceuticals containing TCM in the management of diabetes. However, these results must be interpreted with caution due to the overall low quality of the trials.


Sign in / Sign up

Export Citation Format

Share Document